Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altretamine.

L A Hansen1, T E Hughes

  • 1School of Pharmacy, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298.

DICP : the Annals of Pharmacotherapy
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Altretamine, an oral antineoplastic agent, shows moderate efficacy in advanced ovarian cancer. Its use is limited by toxicities, making it a secondary option when platinum-based chemotherapy is not suitable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in demographics and clinical outcomes in older, middle-aged, and younger adults with low back pain receiving chiropractic care.

Chiropractic & manual therapies·2025
Same author

Think before you prescribe: how dentistry contributes to antibiotic resistance.

Australian dental journal·2019
Same author

Long- and Short-Range Electrostatic Fields in GFP Mutants: Implications for Spectral Tuning.

Scientific reports·2015
Same author

Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.

Diabetes, obesity & metabolism·2015
Same author

The dentition: the outcomes of morphogenesis leading to variations of tooth number, size and shape.

Australian dental journal·2014
Same author

General and craniofacial development are complex adaptive processes influenced by diversity.

Australian dental journal·2014
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Altretamine is an oral antineoplastic agent used for advanced ovarian cancer.
  • It is a lipid-soluble drug metabolized to active cytotoxic species, though the exact mechanism remains unclear.

Purpose of the Study:

  • To review the efficacy and toxicity of altretamine in ovarian cancer treatment.
  • To define the therapeutic role of altretamine, particularly in combination regimens.

Main Methods:

  • Literature review of altretamine's use in ovarian cancer.
  • Analysis of response rates and toxicity profiles from clinical studies.

Main Results:

  • Altretamine shows a 21-39% response rate as a single agent, comparable to other treatments.

Related Experiment Videos

  • Its primary utility is in combination therapy, though evidence from randomized trials is limited.
  • Dose-limiting toxicities include gastrointestinal, hematologic, and neurotoxic effects.

    • Conclusions:

    • Altretamine's therapeutic role is constrained by its toxicity profile, which resembles that of cisplatin.
    • It is best reserved for patients unable to tolerate standard platinum-based chemotherapy regimens.